FR2957803B1 - Diluants adjuvants de vaccins vivants pour maladies porcines - Google Patents

Diluants adjuvants de vaccins vivants pour maladies porcines

Info

Publication number
FR2957803B1
FR2957803B1 FR1052114A FR1052114A FR2957803B1 FR 2957803 B1 FR2957803 B1 FR 2957803B1 FR 1052114 A FR1052114 A FR 1052114A FR 1052114 A FR1052114 A FR 1052114A FR 2957803 B1 FR2957803 B1 FR 2957803B1
Authority
FR
France
Prior art keywords
water
adjuvant
oil
live vaccines
swine diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1052114A
Other languages
English (en)
Other versions
FR2957803A1 (fr
Inventor
Francois Bertrand
Sebastien Deville
Laurent Dupuis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA
Original Assignee
Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1052114A priority Critical patent/FR2957803B1/fr
Application filed by Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA filed Critical Societe dExploitation de Produits pour les Industries Chimiques SEPPIC SA
Priority to BR112012024154A priority patent/BR112012024154A2/pt
Priority to MX2012010851A priority patent/MX342238B/es
Priority to US13/636,741 priority patent/US20130011434A1/en
Priority to PCT/FR2011/050514 priority patent/WO2011117506A2/fr
Priority to RU2012145084/15A priority patent/RU2557968C2/ru
Priority to EP11713006A priority patent/EP2550016A2/fr
Publication of FR2957803A1 publication Critical patent/FR2957803A1/fr
Application granted granted Critical
Publication of FR2957803B1 publication Critical patent/FR2957803B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Procédé de préparation d'une composition vaccinale injectable destinée à combattre le syndrome dysgénésique et respiratoire (SDRP) chez les espèces porcines comprenant au moins l'étape : a) mélange d'un vaccin vivant extemporanément avec un diluant adjuvant (DA) ; caractérisé en ce que ledit diluant adjuvant est une émulsion de type huile dans eau ou une microémulsion de type huile dans eau, ou une solution aqueuse comprenant de l'eau et au moins un sel minéral choisi parmi l'hydroxyde d'aluminium, le nitrate de cérium, le sulfate de zinc, l'hydroxyde de fer colloïdal ou le chlorure de calcium les sels de métaux divalents ou trivalents ou encore de composés sympathomimétiques.
FR1052114A 2010-03-24 2010-03-24 Diluants adjuvants de vaccins vivants pour maladies porcines Active FR2957803B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR1052114A FR2957803B1 (fr) 2010-03-24 2010-03-24 Diluants adjuvants de vaccins vivants pour maladies porcines
MX2012010851A MX342238B (es) 2010-03-24 2011-03-15 Diluyentes adyuvantes para vacunas atenuadas para enfermedades porcinas.
US13/636,741 US20130011434A1 (en) 2010-03-24 2011-03-15 Adjuvant diluents for live vaccines for pig diseases
PCT/FR2011/050514 WO2011117506A2 (fr) 2010-03-24 2011-03-15 Diluants adjuvants de vaccins vivants pour maladies porcines
BR112012024154A BR112012024154A2 (pt) 2010-03-24 2011-03-15 diluentes adjuvantes para vacinas vivas para doenças de porcos
RU2012145084/15A RU2557968C2 (ru) 2010-03-24 2011-03-15 Адъюванты-разбавители для живых вакцин от болезней свиней
EP11713006A EP2550016A2 (fr) 2010-03-24 2011-03-15 Diluants adjuvants de vaccins vivants pour maladies porcines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1052114A FR2957803B1 (fr) 2010-03-24 2010-03-24 Diluants adjuvants de vaccins vivants pour maladies porcines

Publications (2)

Publication Number Publication Date
FR2957803A1 FR2957803A1 (fr) 2011-09-30
FR2957803B1 true FR2957803B1 (fr) 2012-06-01

Family

ID=42635539

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1052114A Active FR2957803B1 (fr) 2010-03-24 2010-03-24 Diluants adjuvants de vaccins vivants pour maladies porcines

Country Status (7)

Country Link
US (1) US20130011434A1 (fr)
EP (1) EP2550016A2 (fr)
BR (1) BR112012024154A2 (fr)
FR (1) FR2957803B1 (fr)
MX (1) MX342238B (fr)
RU (1) RU2557968C2 (fr)
WO (1) WO2011117506A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103059073A (zh) * 2012-12-14 2013-04-24 江苏省海安石油化工厂 失水甘露醇油酸酯的制备方法
FR3012964A1 (fr) * 2013-11-12 2015-05-15 Seppic Sa Vaccins adjuves pour vaccination aviaire in ovo
WO2019212378A1 (fr) * 2018-05-04 2019-11-07 Farber Boris Slavinovich Vaccins à immunogénicité élevée à faible risque d'allergie et de réactions
CN110665000B (zh) * 2018-07-02 2022-11-11 厦门大学 锌铝复合佐剂的制备及作为疫苗佐剂的用途
FR3107454B1 (fr) * 2020-02-20 2023-02-10 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Adjuvant de vaccin comprenant un microlatex inverse
CN113371753A (zh) * 2021-06-07 2021-09-10 江苏农林职业技术学院 一种纳米锌及其绿色合成方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8301996A (nl) * 1983-06-06 1985-01-02 Duphar Int Res Werkwijze ter bereiding van geadjuveerde levende vaccins en aldus verkregen geadjuveerde levende vaccins.
US6676958B2 (en) * 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
PL1613346T3 (pl) * 2003-04-04 2013-03-29 Zoetis Services Llc Poddane mikrofluidyzacji emulsje typu olej w wodzie i kompozycje szczepionek
NZ545289A (en) * 2003-07-24 2008-05-30 Merial Ltd Vaccine formulations comprising an oil-in-water emulsion
RU2269361C2 (ru) * 2004-03-25 2006-02-10 Федеральное государственное учреждение "Федеральный центр охраны здоровья животных" (ФГУ ВНИИЗЖ) Вакцина ассоциированная эмульсионная инактивированная против репродуктивно-респираторного синдрома и парвовирусной инфекции свиней
ES2343201T3 (es) * 2005-01-13 2010-07-26 Boehringer Ingelheim Vetmedica Gmbh Vacunas contra el srrp.
DK2310046T3 (da) * 2008-06-27 2016-04-25 Zoetis Services Llc Hidtil ukendte adjuvanssammensætninger

Also Published As

Publication number Publication date
RU2012145084A (ru) 2014-04-27
BR112012024154A2 (pt) 2016-06-28
MX2012010851A (es) 2013-04-03
US20130011434A1 (en) 2013-01-10
WO2011117506A2 (fr) 2011-09-29
WO2011117506A3 (fr) 2011-11-17
RU2557968C2 (ru) 2015-07-27
FR2957803A1 (fr) 2011-09-30
EP2550016A2 (fr) 2013-01-30
MX342238B (es) 2016-09-21

Similar Documents

Publication Publication Date Title
FR2957803B1 (fr) Diluants adjuvants de vaccins vivants pour maladies porcines
CR20220609A (es) Antagonistas del receptor de lpa y usos de los mismos
MX2020012041A (es) Formulacion farmaceutica.
JP2020507589A5 (fr)
JP2018538653A5 (fr)
BRPI0511327B8 (pt) combinações de glicopirrolato e agonistas do adrenorreceptor beta2
WO2008136019A3 (fr) Procédé pour la préparation d'une silice précipitée finement divisée
JP2011140525A5 (fr)
JP2012502064A5 (fr)
BR112015000475A2 (pt) métodos de indução de anestesia
PE20211595A1 (es) Compuestos de 2,6-diaminopiridina
JP2019512515A5 (fr)
PH12015501793A1 (en) Bicyclic compounds
Hinz et al. High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome
BR112018011331A2 (pt) mutante de proteìna l1 de papillomavirus humano tipo 11
JP2013517224A5 (fr)
BR112014004261A2 (pt) diagnósticos de vacina melhorada
RU2012145081A (ru) Живая вакцина против заболеваний птиц
HRP20201952T1 (hr) Mješovite soli hidroksi-alkanske sulfinske kiseline
RU2017114678A (ru) Перорально распадающаяся твердая фармацевтическая единица дозирования, содержащая контролирующее родовую деятельность вещество
JP2017534609A5 (fr)
BR0308674A (pt) Métodos para preparar catalisador de cianeto metálico usando sais metálicos insolúveis
EP3593650A3 (fr) Préparations pour l`augmentation du ph dans un aliment par la génération d`hydrogène moléculaire
Barraclough et al. Hepatitis B virus infection in hemodialysis populations: progress toward prevention
CN105396131A (zh) 一种用于呼肠孤灭活疫苗的佐剂及其制备方法

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15